BACKGROUND: To define the mortality and the current impact of the H1N1 pandemic in pediatric hematology-oncology centers, we performed a specific survey. PROCEDURE: Pharyngeal swabs from patients with fevers of unknown origin, flu-like symptoms or bronchopneumonia were screened for H1N1 using PCR. RESULTS: Sixty-two patients with documented H1N1 infection were reported: 16 had recently stopped therapy, 2 were at the diagnosis stage, and 44 were receiving therapy. The clinical course was severe (requiring ICU admission) in only 1 patient, moderate (requiring hospital admission) in 38, and mild in the remaining 23 (37%), treated as outpatients. While none of the patients died of H1N1-related complications, two patients died of progressive cancer; in all of the remaining cases, symptoms resolved within 11 days. The clinical course was complicated by respiratory distress or bronchopneumonia in 10 cases. Oseltamivir was given to 82% of patients. Chemotherapy was temporarily withdrawn in 54% of cases for a median time of 21 days (range, 4-43 days). CONCLUSION: H1N1 infection in children with cancer was not reported as the cause of death in any case but resulted in reduced intensity of anti-cancer therapy. (c) 2010 Wiley-Liss, Inc.
BACKGROUND: To define the mortality and the current impact of the H1N1 pandemic in pediatric hematology-oncology centers, we performed a specific survey. PROCEDURE: Pharyngeal swabs from patients with fevers of unknown origin, flu-like symptoms or bronchopneumonia were screened for H1N1 using PCR. RESULTS: Sixty-two patients with documented H1N1infection were reported: 16 had recently stopped therapy, 2 were at the diagnosis stage, and 44 were receiving therapy. The clinical course was severe (requiring ICU admission) in only 1 patient, moderate (requiring hospital admission) in 38, and mild in the remaining 23 (37%), treated as outpatients. While none of the patients died of H1N1-related complications, two patients died of progressive cancer; in all of the remaining cases, symptoms resolved within 11 days. The clinical course was complicated by respiratory distress or bronchopneumonia in 10 cases. Oseltamivir was given to 82% of patients. Chemotherapy was temporarily withdrawn in 54% of cases for a median time of 21 days (range, 4-43 days). CONCLUSION:H1N1infection in children with cancer was not reported as the cause of death in any case but resulted in reduced intensity of anti-cancer therapy. (c) 2010 Wiley-Liss, Inc.
Authors: Dat Tran; Michelle Science; David Dix; Carol Portwine; Shayna Zelcer; Donna L Johnston; Rochelle Yanofsky; Adam Gassas; Marie-Chantal Ethier; Lillian Sung Journal: Influenza Other Respir Viruses Date: 2012-03-14 Impact factor: 4.380
Authors: Per Ljungman; Rafael de la Camara; Lena Perez-Bercoff; Manuel Abecasis; Jose Bartolo Nieto Campuzano; M Jimena Cannata-Ortiz; Catherine Cordonnier; Hermann Einsele; Marta Gonzalez-Vicent; Ildefonso Espigado; Jörg Halter; Rodrigo Martino; Bilal Mohty; Gülsan Sucak; Andrew J Ullmann; Lourdes Vázquez; Katherine N Ward; Dan Engelhard Journal: Haematologica Date: 2011-05-05 Impact factor: 9.941
Authors: Seok Jeong Kang; Jae Min Lee; Jeong Ok Hah; Ye Jee Shim; Kun Soo Lee; Hyun Jung Shin; Heung Sik Kim; Eun Jin Choi; So Eun Jeon; Young Tak Lim; Ji Kyeong Park; Eun Sil Park Journal: Korean J Pediatr Date: 2011-03-31
Authors: Helen Y Chu; Christian Renaud; Elle Ficken; Blythe Thomson; Jane Kuypers; Janet A Englund Journal: J Pediatric Infect Dis Soc Date: 2014-10-21 Impact factor: 3.164